Sino Biopharmaceutical

Sino Biopharmaceutical (1177.HK) - The Business, The Concerns, The Insights on Biopharma Valuation

Equity Bottom-Up
161 Views, 07 Dec 2021 09:00
EXECUTIVE SUMMARY
  • We analyzed the business performance and short-term catalyst for Sino Biopharmaceutical (1177 HK), and investors could decide whether to take advantage of it or not.
  • We also analyzed the concerns about the Company as well as our insights on the valuation of biopharmaceutical companies.
  • Based on our analysis, we are conservative about the Company’s outlook at the current stage.
detail (5-minute read)
WHAT’S TRENDING
logo
Logo
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
ChinaHealth CareEquity Bottom-UpThematic (Sector/Industry)

Over 13 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in ... 

x